LivaNova PLC To Present At The Jefferies And Piper Jaffray Conferences

LivaNova PLC (NASDAQ: LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today announced Damien McDonald, incoming Chief Executive Officer of LivaNova, and Vivid Sehgal, Chief Financial Officer of LivaNova, will both participate in discussions at the Jefferies London Healthcare Conference in London on Wednesday, November 16, 2016 and the Piper Jaffray Healthcare Conference in New York City on Tuesday, November 29, 2016.

The discussion at the Jefferies Healthcare Conference is scheduled to begin at 8:00 a.m. Greenwich Mean Time on Wednesday, November 16, 2016 and the discussion at the Piper Jaffray Healthcare Conference is scheduled to begin at 11:00 a.m. Eastern Standard Time on Tuesday, November 29, 2016. Both discussions will be available to all interested parties through a live audiocast accessible via the investor relations section of LivaNova's website at www.livanova.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. A replay of the webcast will be available on the LivaNova website approximately 24 hours after the live presentation for 90 days after the event.

About LivaNova

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K.

For more information, please visit www.livanova.com .

View source version on businesswire.com: http://www.businesswire.com/news/home/20161111005631/en/
Copyright Business Wire 2010

If you liked this article you might like

Biotech Movers: Fate Shares Spike After Cancer Studies Progress

Biotech Movers: Fate Shares Spike After Cancer Studies Progress